Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

(Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z \xrightarrow{A''_n} X \xrightarrow{A''_n} X'$$

$$R''$$

$$\begin{bmatrix} 1 \end{bmatrix}$$

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a and b represent double bonds which may be present or absent; when present, the double bonds may

be in the E or Z configuration and, when absent, the resulting stereocenters may have the R-or S-configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2 Z'; - CO_2 R'''; - NH_2 ; - NH_2 '''; - NR_2 '''; -OH; -OR'''; - $CONR_2$ '''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

R'''' independently represents a hydrogen atom; optionally substituted C_1 - C_{20} alkyl; optionally substituted C_1 - C_{20} alkoxy; optionally substituted C_2 - C_{20} alkenyl; optionally substituted C_6 - C_{10} aryl; or NR_2 ''' represents a cyclic moiety. moiety;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;



or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

(Currently amended) A method according to claim 61, wherein R' represents -CO₂R'''; -CO₂R''', -CO₂Z' or -CONR₂'''' wherein R''' represents hydrogen or methylor at least one R''' independently represents a hydrogen atom, methyl, or methoxy.

- 63. (Cancelled)
- 64. (Cancelled)
- 3 65. (Previously presented) A method according to claim 61, wherein X is -S- and X' is >NH.
- (Previously presented) A method according to claim 62, wherein X is -S- and X' is >NH.
- 56. (Currently amended) A method according to claim 63 115, wherein X is -S- and X' is >NH.
- (Currently amended) A method according to claim 64 117, wherein X is -S- and X' is >NH.
- (Currently amended) A method according to claim 62.61, wherein the bond labeled "a" in formula 1 a represents a single bond and b represents a double bond.
- (Currently amended) A method according to claim 62 61, wherein at least two one A group represents groups represent methoxy.

(Currently amended) A method according to claim 62, wherein at least two A groups represent a hydrogen bond atom.

(Currently amended) A method according to claim 70, wherein at least two A groups represent a hydrogen bond atom.

(Currently amended) A method according to claim 61, wherein R' is carbomethoxy and 116 wherein said A is group represents methoxy.

(Currently amended) The method of claim 61 118 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

(Currently amended) The method of claim 62 70 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

(Previously presented). A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A''_n \\ A''_n$$

in a physiologically acceptable carrier;

[1]

wherein Z is

H; A"; or B";

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a and b represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R-or S- configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 ''; - NH_2 '''; - NH_2 ''''; - NH_2 '''''; - NH_2 '

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 "; -NH

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

R'''' independently represents a hydrogen atom; optionally substituted C_1 - C_{20} alkyl; optionally substituted C_1 - C_{20} alkoxy; optionally substituted C_2 - C_{20} alkenyl; optionally substituted C_6 - C_{10} aryl; or NR_2 '''' represents a cyclic moiety. moiety;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, and A' each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

A" independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylcarboxylamino; carboxyl; cyano; or halo;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

(Currently amended) A method according to claim 76, wherein R' represents

-CO₂R'''; -CO₂R'''; -CO₂Z' or -CONR₂'''' wherein R''' represents hydrogen or methyl-or at least one R'''' independently represents a hydrogen atom, methyl, or methoxy.

78. (Cancelled)

Application No. 0 Supplemental Ame Page 8	9/843,167 endment dated September 17, 2003
L (Current)	y amended) A method according to claim 137 76, wherein R' represents
methoxy.	ein both R''' are the same and represent a hydrogen atom, methyl, or
Л	14
	sly presented) A method according to claim \mathcal{H} , wherein X is -S- and X' is
>NH.	
·\$.	(5
81. (Previous	sly presented) A method according to claim \mathcal{H} , wherein X is -S- and X' is
>NH.	
.a	70
19 82. (Currentl	y amended) A method according to claim 78 133, wherein X is -S- and X'
is >NH.	
ገ ፆ	72
%3. (Currentl	y amended) A method according to claim 79 135, wherein X is -S- and X'
is >NH.	
۸ ا	14
84. (Currentl	y amended) A method according to claim 77 76, wherein the bond labeled
"a" in formula 1	a represents a single bond and b represents a double bond.
ν	
985. (Currentl	y amended) A method according to claim M, wherein at least two one A
	-group represents methoxy.
1	. <
ヮう ~&6. (Currentl	y amended) A method according to claim, M, wherein at least two A groups
represent a hydro	
ĹZ	22
义 87. (Currentl	y amended) A method according to claim, 85, wherein at least two A groups
	ogen bond atom.

(Currently amended) A method according to claim 76, wherein R' is carbomethoxy and 134 wherein said A group represents is methoxy.

73

(Currently amended) The method of claim 76 136 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

(Currently amended) The method of claim 77.85 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

(Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

in a physiologically acceptable carrier;

wherein Z is

or

$$A_p$$
 C
 R'
 B_s

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a, b and c represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R independently represents a hydrogen atom; linear or branched C₁-C₂₀ alkyl; linear or branched C₂-C₂₀ alkenyl; -CO₂Z'; -CO₂R'''; -NH₂; -NHR'''; -NR₂'''; -OH; -OR'''; -CONR₂''''; halogen atom; optionally substituted linear or branched C₁-C₂₀ alkyl; optionally substituted linear or branched C₂-C₂₀ alkenyl;

R' independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ''; - NR_2''' ; -OR'''; - $CONR_2'''$; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 "; -NH

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

R'''' independently represents a hydrogen atom; optionally substituted C_1 - C_{20} alkyl; optionally substituted C_1 - C_{20} alkoxy; optionally substituted C_2 - C_{20} alkenyl; optionally substituted C_6 - C_{10} aryl; or NR_2 ''' represents a cyclic moiety. moiety;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkoxy; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR", -O-, or -S-.

(Currently amended) A method according to claim 91, wherein R' represents

-CO₂R'''; -CO₂R''', -CO₂Z' or -CONR₂'''' wherein R''' represents hydrogen or methyl or
at least one R'''' independently represents a hydrogen atom, methyl, or methoxy.

(Currently amended) A method according to claim 150 91, wherein R' represents -CO₂R''' wherein R''' represents hydrogen or methyl.

(Currently amended) A method according to claim 154 91, wherein R' represents CONR₂" wherein both R" are the same and represent a hydrogen atom, atom or methyl, or methoxy.

Application No. 09/843,167 Supplemental Amendment dated September 17, 2003 Page 12 (Previously presented) A method according to claim 91, wherein X is -S- and X' is >NH. (Previously presented) A method according to claim 92, wherein X is -S- and X' is >NH. (Currently amended) A method according to claim 93 150, wherein X is -S- and X' is >NH. (Currently amended) A method according to claim 94 $\underline{152}$, wherein X is -S- and X' is >NH. (Currently amended) A method according to claim 92, wherein the bond labeled "a" a represents a single bond and b represents a double bond. (Currently amended) A method according to claim 92, wherein at least two one A groups represent group represents methoxy. (Currently amended) A method according to claim 92, wherein at least two A groups represent a hydrogen bond atom. (Currently amended) A method according to claim 100, wherein at least two A groups represent a hydrogen bond atom. 193. (Currently amended) A method according to claim 91, wherein R' is carbomethoxy and 151 wherein said A is-group represents methoxy.

104. (Currently amended) The method of claim 91 153 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

105. (Currently amended) The method of claim 92 100 wherein said pharmaceutically acceptable counter ion is selected from sodium, potassium, calcium, magnesium, ammonium, tromethamine, or tetramethylammonium.

106. (Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A''_n & A''_n$$

in a physiologically acceptable carrier;

wherein Z is

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a and b represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R-or S-configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 ''; - NR_2 '''; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C₁-C₂₀ acylamino; C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl; C₁-C₂₀ alkoxycarbonyl; C₁-C₂₀ alkoxy; C₁-C₂₀ alkylamino; C₁-C₂₀ alkylamino; C₁-C₂₀ alkylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

43 107. (Currently amended) A method according to claim 106, wherein R' represents -CO₂R''' or -CO₂Z'-wherein-R''' represents hydrogen or methyl. 43
108. (Previously presented) A method according to claim 106, wherein X is -S- and X' is

>NH. (Previously presented) A method according to claim 100, wherein X is -S- and X' is

(Previously presented) A method according to claim 107, wherein X is -S- and X' is >NH.

(Previously presented). A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A''_n \\ B''_m \end{bmatrix} X$$

$$A''_n \\ A''_n \\ A'$$

in a physiologically acceptable carrier;

wherein Z is

H; A"; or B";

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a and b

Application No. 09/843,167

Supplemental Amendment dated September 17, 2003

Page 16

represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R-or S- configuration;

R and R' each independently represent a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R'' independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; -NHR'''; - NR_2''' ; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, and A' each independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylamino; carboxyl; cyano; halo; or hydroxy;

A" independently represent a hydrogen atom; C_1 - C_{20} acylamino; C_1 - C_{20} acyloxy; C_1 - C_{20} alkanoyl; C_1 - C_{20} alkoxycarbonyl; C_1 - C_{20} alkylamino; C_1 - C_{20} alkylcarboxylamino; carboxyl; cyano; or halo;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR'", -O-, or -S-.

(Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of a compound represented by the following formula 1:

$$Z = \begin{bmatrix} A''_n & A''_n$$

in a physiologically acceptable carrier;

wherein Z is

or

Application No. <u>09/843,167</u>

Supplemental Amendment dated September 17, 2003

Page 18

$$A_{p}$$

$$C$$

$$R'$$

$$B_{s}$$

n, m, q and r independently represent integers from zero to 4 provided that $n + m \le 4$ and $q + r \le 4$; p and s independently represent integers from zero to 5 provided that $p + s \le 5$; a, b and c represent double bonds which may be present or absent; when present, the double bonds may be in the E or Z configuration and, when absent, the resulting stereocenters may have the R- or S- configuration;

R independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 ''; - NH_2 ''; -OH; -OR'''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R' independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 '''; - NR_2 '''; -OR'''; - $CONR_2$ '''; halogen atom; optionally substituted linear or branched C_1 - C_{20} alkyl; optionally substituted linear or branched C_2 - C_{20} alkenyl;

R" independently represents a hydrogen atom; linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; - CO_2Z' ; - CO_2R''' ; - NH_2 ; - NH_2 ; - NH_2 "; -NH

R''' independently represents a linear or branched C_1 - C_{20} alkyl; linear or branched C_2 - C_{20} alkenyl; or $-(CH_2)_x$ -Ar, where x represents an integer from 1 to 6 and Ar represents aryl;

Z' represents a hydrogen atom or a pharmaceutically acceptable counter-ion;

A, A' and A" each independently represent a hydrogen atom; C₁-C₂₀ acylamino; C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl; C₁-C₂₀ alkoxycarbonyl; C₁-C₂₀ alkoxy; C₁-C₂₀ alkylamino; C₁-C₂₀ alkylamino; C₁-C₂₀ alkylamino; carboxyl; cyano; halo; or hydroxy;

B, B' and B" each independently represent; C_2 - C_{20} alkenoyl; aroyl; aralkanoyl; nitro; optionally substituted, linear or branched C_1 - C_{20} alkyl; or optionally substituted, linear or branched C_2 - C_{20} alkenyl;

or A and B jointly, A' and B' jointly, or A" and B" jointly, independently represent a methylenedioxy or ethylenedioxy group; and

X and X' independently represent >NH, >NR", -O-, or -S-.

(Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylic acid in a physiologically acceptable carrier.

173. (Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-acrylamide in a physiologically acceptable carrier.

(Previously presented) A method of treating diabetes comprising the steps of administering to a subject suffering from a diabetic condition, a therapeutically effective amount of 5-(4-(4-(1-carbomethoxy-2-)3,5-dimethoxy phenyl) ethenyl)-phenoxy)-benzyl)-2,4-thiazolidinedione in a physiologically acceptable carrier.

(New) A method according to claim 62 wherein R' represents -CO₂R'''.

Application No. 09/843,167 Supplemental Amendment dated September 17, 2003 Page 20 (New) A method according to claim 115 wherein R'" represents methyl. (New) A method according to claim 62 wherein R' represents -CO₂Z'. (New) A method according to claim 1117 wherein Z' is a pharmaceutically acceptable counter ion. (New) A method according to claim 62 wherein R' represents -CONR₂'''. (New) A method according to claim 119 wherein at least one R''' independently represents a hydrogen atom, methyl or methoxy. (New) A method according to claim 1,19, wherein both R''' are the same and represent a hydrogen atom or methyl. (New) A method according to claim 149, wherein X is -S- and X' is >NH. (New) A method according to claim 61 wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method according to claim,69 wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method of claim 61 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim 68 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim 119 wherein the bond labeled "b" in formula 1 represents a

double bond and the bond labeled "a" in formula 1 represents a single bond.

,)

128. (New) A method of claim 62 wherein at least two A groups represent methoxy.

129. (New) A method of claim 61 wherein A' and B' represent hydrogen atoms.

130. (New) A method of claim 61 wherein A" and B" represent hydrogen atoms.

131. (New) A method of claim 61 wherein A', A", B' and B" all represent hydrogen atoms.

(New) A method according to claim 125 wherein A', A", B' and B" all represent hydrogen atoms.

133. (New) A method according to claim 71 wherein R' represents -CO₂R'''.

134. (New) A method according to claim 133 wherein R''' represents methyl.

135. (New) A method according to claim 77 wherein R' represents -CO₂Z'.

136. (New) A method according to claim 135 wherein Z' is a pharmaceutically acceptable counter ion.

المجاري المحاري (New) A method according to claim H wherein R' represents -CONR₂''''.

(New) A method according to claim 137 wherein at least one R''' independently represents a hydrogen atom, methyl or methoxy.

139. (New) A method according to claim 137, wherein both R''' are the same and represent a hydrogen atom or methyl.

Application No. 09/843,167 Supplemental Amendment dated September 17, 2003 Page 22 (New) A method according to claim 16 wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method according to claim 84 wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method of claim 133 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim 135 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim 137 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim M wherein at least two A groups represent methoxy. (New) A method of claim Wherein A' and B' represent hydrogen atoms. (New) A method of claim 76 wherein A" and B" represent hydrogen atoms. (New) A method of claim 16 wherein A', A", B' and B" all represent hydrogen atoms. (New) A method according to claim 133 wherein A', A", B' and B" all represent hydrogen atoms. (New) A method according to claim 92 wherein R' represents -CO₂R'". (New) A method according to claim 150 wherein R''' represents methyl.

Application No. 09/843,167 Supplemental Amendment dated September 17, 2003 Page 23 (New) A method according to claim 92 wherein R' represents -CO₂Z'. (New) A method according to claim 152 wherein Z' is a pharmaceutically acceptable counter ion. (New) A method according to claim 92 wherein R' represents -CONR2"". (New) A method according to claim 154 wherein at least one R''' independently represents a hydrogen atom, methyl or methoxy. (New) A method according to claim 158 wherein both R''' are the same and represent a hydrogen atom or methyl. (New) A method according to claim 154, wherein X is -S- and X' is >NH. (New) A method according to claim of wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method according to claim 99 wherein the bond labeled "b" in formula 1 represents a double bond. (New) A method of claim 150 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method of claim 152 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. 91 (New) A method of claim 184 wherein the bond labeled "b" in formula 1 represents a double bond and the bond labeled "a" in formula 1 represents a single bond. (New) A method according to claim 107 wherein R' represents -CO₂R'".

```
Application No. 09/843,167
Supplemental Amendment dated September 17, 2003
                                            100
       (New) A method according to claim 163 wherein R'" represents methyl.
       (New) A method according to claim 107 wherein R' represents -CO<sub>2</sub>Z'.
       (New) A method according to claim 165 wherein Z' is a pharmaceutically acceptable
counter ion.
       (New) A method according to claim 163, wherein X is -S- and X' is >NH.
       (New) A method according to claim 165, wherein X is -S- and X' is >NH.
       (New) A method of treating diabetes comprising the steps of administering to a
subject suffering from a diabetic condition, a therapeutically effective amount of 3-(3,5-
dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5ylmethyl)-phenoxy]-phenyl}-N,N-
dimethyl-acrylamide in a physiologically acceptable carrier.
       (New) A method of claim 2 wherein said compound is selected from the group
consisting of 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-
phenyl}-acrylic acid,
3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-
phenyl}-acrylamide,
3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-
phenyl}-N,N-dimethyl-acrylamide,
3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxyl-
phenyl}-N-methoxy,-N-methyl-acrylamide,
3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-
phenoxy]-phenyl}-propionic acid methyl ester,
```

3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxy]-phenyl}-acrylic acid methyl ester,

3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid,

3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolid in-5-ylidenemethyl)-phenoxy]-phenyl}-propionic acid,

3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-phenoxy]-phenyl}-acrylic acid, and

3-(3,5-dimethoxy-phenyl)-2-{4-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-phenyl}-propionic acid methyl ester.

once of